ArticleAbdominal radiology (New York)2026
Combined dual-phase CT radiomics and deep transfer learning model for oxaliplatin response in unresectable colorectal liver metastases.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a multivariable CT-based Delta-radiomics model for predicting efficacy to bevacizumab therapy in patients with colorectal liver metastases.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesAccurate prediction of response to first-line oxaliplatin-based chemotherapy in unresectable colorectal liver metastases (CRLM) is critical for optimizing treatment strategies. This study aimed to develop and validate a dual-phase CT-based Combined model integrating radiomics, deep transfer learning (DTL), and clinical variables to enable individualized response prediction.
methodsIn this multicenter retrospective study, 360 patients with unresectable CRLM were enrolled from three medical centers. Patients from one center were randomly divided into a training cohort (n = 199) and an internal validation cohort (n = 86), while an independent external test cohort (n = 75) was composed of patients from two separate institutions. Radiomics and DTL features were extracted from arterial and portal venous phase CT images. A Combined model was developed by integrating radiomics, DTL outputs, and clinical variables. Model performance was evaluated through AUC, accuracy, specificity, sensitivity, and clinical utility.
resultsThe Combined model achieved AUCs of 0.928 (95% CI: 0.894-0.963), 0.899 (95% CI: 0.834-0.964), and 0.858 (95% CI: 0.776-0.941) in the training, internal validation, and external test cohorts, respectively. It consistently outperformed the radiomics, DTL, and Clinical models in most cohorts, with favorable calibration and greater clinical benefit across decision thresholds.
conclusionWe developed and validated a dual-phase CT Combined model that enables accurate early prediction of chemotherapy response in unresectable CRLM. By facilitating early identification of patients with non-objective response, this approach provides a non-invasive and clinically feasible tool to support individualized treatment planning, guide timely treatment modification, and ultimately improve patient outcomes.
Indexed as
Identifiers
41251740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.